Governance Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-10 pm EDT			5-day change	1st Jan Change
291.22 ^USD	-2.17%		+1.78%	-26.76%

08:10am	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

Executive Committee: Alnylam Pharmaceuticals, Inc.

Manager

Positions heldSince

Yvonne Greenstreet

63 year

Chief Executive Officer

2021-12-31

Bryan Supran

General Counsel	2025-08-31
Corporate Secretary	2025-08-31

Melissa McLaughlin

Human Resources Officer

2024-12-31

Timothy J. Maines

Chief Tech/Sci/R&D Officer

2023-03-31

Piyush Sharma

Compliance Officer

2022-09-20

Jeffrey Poulton

58 year

Comptroller/Controller/Auditor	2019-08-12
Director of Finance/CFO	2019-08-12

Kevin Fitzgerald

58 year

Chief Tech/Sci/R&D Officer

2016-08-31

Joshua Brodsky

Investor Relations Contact	2021-01-31
Public Communications Contact	2021-01-31

Pushkal Garg

58 year

Chief Tech/Sci/R&D Officer

2014-10-28

Composition of the Board of Directors: Alnylam Pharmaceuticals, Inc.

Director

CommitteesSince

Amy Schulman

65 year

Compensation Committee	2015-06-30
HR Committee
Governance Committee
Nominating Committee
Audit Committee	2026-01-11
Compensation Committee Chair	2021-01-24
Finance Committee	2026-01-11

David Pyott

72 year

Executive Committee	2011-04-06
Governance Committee Chair
Nominating Committee Chair
Audit Committee
Governance Committee
Nominating Committee	2026-02-17
Compensation Committee	2026-02-17

Colleen Reitan

66 year

Audit Committee	2019-09-24
Compensation Committee Chair
HR Committee Chair
Compensation Committee	2019-08-25
Finance Committee	2019-09-24
Governance Committee Chair	2019-09-24
Nominating Committee Chair	2019-09-24

Dennis Ausiello

80 year

Governance Committee
Nominating Committee	2021-12-29
Audit Committee	2021-12-29
Compensation Committee	2021-12-29
Finance Committee	2021-12-29

Charles Sigal

74 year

Governance Committee	2020-06-07
Nominating Committee	2020-06-07
Compensation Committee
HR Committee

Stuart Arbuckle

60 year

Executive Committee
Compensation Committee	2026-02-05
Governance Committee Chair
Nominating Committee Chair

Olivier Brandicourt

70 year

Audit Committee	2024-01-21
Compensation Committee	2020-03-01
HR Committee	2020-03-01

Margaret Hamburg

70 year

Governance Committee	2019-01-09
Nominating Committee	2019-01-09

Benjamin Cravatt

56 year

Compensation Committee Chair

2013-12-31

Peter Kellogg

69 year

Audit Committee Chair

2023-09-28

Yvonne Greenstreet

63 year

Director/Board Member

2021-10-27

Latest Appointments: Alnylam Pharmaceuticals, Inc.

May. 27	Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026	CI
Apr. 06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
Jan. 08	Praxis Precision Medicines, Inc. Announces Management and Committees Changes	CI
Dec. 10	Elevance Health Announces Appointment of Amy Schulman as Independent Director, Effective January 12, 2026	CI
Dec. 03	Alnylam Pharmaceuticals Announces Changes to Board of Directors	CI
Dec. 03	Alnylam Pharmaceuticals announces changes to board of directors	RE
25-06-18	Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	CI

More news

Former Officers and Directors: Alnylam Pharmaceuticals, Inc.

Insider

Positions held

SinceUntil

Michael Bonney

Director/Board Member	2023-01-04	2025-12-01
Chairman	2015-11-30	2023-01-04
Independent Dir/Board Member	2014-12-16	2023-01-04

Steven A. Bossone

Corporate Officer/Principal

2010-07-31

2025-07-31

Phillip Sharp

Director/Board Member	2002-06-13	2025-05-07
Founder	2002-06-13	2025-05-07
Independent Dir/Board Member	2002-06-13	2025-05-07

Akshay Vaishnaw

Chief Tech/Sci/R&D Officer	2005-12-31	2022-01-03
Corporate Officer/Principal	2023-10-01	2024-11-30
President	2022-01-03	2023-10-01

James Bilotta

Chief Tech/Sci/R&D Officer

2015-09-30

2024-07-31

Sara Nochur

General Counsel	2005-12-31	2020-12-31
Corporate Officer/Principal	2020-12-31	2024-04-30

Marsha Fanucci

Director/Board Member	2010-12-07	2023-09-28
Independent Dir/Board Member	2010-12-07	2023-09-28

Al Boyle

Chief Tech/Sci/R&D Officer

2015-11-30

2023-03-31

Steven Paul

Director/Board Member	2010-09-21	2022-04-15
Independent Dir/Board Member	2010-09-21	2022-04-15

John Maraganore

Director/Board Member	2002-11-30	2021-12-30
Chief Executive Officer	2002-11-30	2021-12-30
Founder	2002-11-30	2021-12-30
President	2002-11-30	2007-11-30

Laurie Keating

General Counsel	2014-09-16	2021-09-09
Corporate Secretary	2014-09-16	2021-09-09

Barry Greene

Chief Operating Officer	2003-09-30	2016-09-18
President	2003-09-30	2020-09-29

Paul Schimmel

Director/Board Member	2002-06-13	2020-05-05
Founder	2002-06-13	2020-05-05
Independent Dir/Board Member	2002-06-13	2020-05-05

Nereyda Garcia

Compliance Officer

2015-12-31

2019-11-30

Mike Mason

Comptroller/Controller/Auditor	2005-11-30	2018-09-30
Director of Finance/CFO	2005-12-01	2016-05-31
Treasurer	2011-01-31	2019-01-31

John Clarke

Director/Board Member	2002-06-13	2019-01-09
Chairman	2002-06-13	2015-12-31
Founder	2002-06-13	2019-01-09
Independent Dir/Board Member	2002-06-13	2019-01-09

Karen Anderson

Human Resources Officer

2014-09-16

2018-12-31

Kevin Starr

Director/Board Member	2003-08-31	2018-02-28
Independent Dir/Board Member	2003-08-31	2018-02-28

David-Alexandre Gros

Director of Finance/CFO	2016-06-30	2017-01-05
Corporate Officer/Principal	2015-06-07	2016-06-30

Mark Baglin

Sales & Marketing

2016-12-31

Benny Sorensen

Chief Tech/Sci/R&D Officer

2015-06-30

2016-09-30

Susanna High

Director/Board Member	2007-01-31	2008-05-31
Corporate Officer/Principal	2008-05-31	2016-08-31

Emmanuel Dulac

Corporate Officer/Principal

2016-08-18

Oved Amitay

Corporate Officer/Principal

2012-06-26

2016-05-31

Laurence Reid

Corporate Officer/Principal

2010-06-03

2014-12-30

Marko Kinchen Kozul

Corporate Officer/Principal

2014-09-16

Victor J. Dzau

Director/Board Member	2007-03-31	2014-06-29
Independent Dir/Board Member	2007-03-31	2014-06-29

Varun Kumar

Corporate Officer/Principal

2011-03-31

2014-01-31

Pritesh Gandhi

Chief Tech/Sci/R&D Officer

2013-12-31

Aria Tavana

Corporate Officer/Principal

2012-12-31

Nessan Bermingham

Corporate Officer/Principal

2012-04-29

Dinah Sah

Chief Tech/Sci/R&D Officer	2005-03-31	2011-12-31
Private Equity Investor	2009-12-31	2011-12-31

Kenneth S. Koblan

Chief Tech/Sci/R&D Officer	2010-12-19	2011-06-01
Corporate Officer/Principal	2010-06-03	2010-12-19

Vicki Sato

Director/Board Member

2005-11-30

2011-04-29

Patricia Allen

Director of Finance/CFO	2004-04-30	2010-09-26
Treasurer	2004-04-30	2011-02-27

James L. Vincent

Director/Board Member

2005-06-30

2010-09-21

Garvin L. Warner

Corporate Officer/Principal

2010-07-31

Ed Scolnick

Director/Board Member

2008-01-31

2010-01-31

Antonin Rollet de Fougerolles

Chief Tech/Sci/R&D Officer

2002-12-31

2009-12-31

Jason Rhodes

Corporate Officer/Principal

2007-06-30

2009-12-31

John Schmidt

Chief Tech/Sci/R&D Officer

2008-09-30

2009-09-29

Peter J. Williams

Corporate Officer/Principal

2005-12-31

Nagesh Mahanthappa

Corporate Officer/Principal

2002-07-31

2007-01-31

Eric W. Raichle

Human Resources Officer

2006-12-31

Mary DeLena

Corporate Officer/Principal

2006-12-31

John Berriman

Director/Board Member

2003-06-30

2005-12-06

Cynthia Clayton

Investor Relations Contact

2004-12-31

Robert A. Millman

Corporate Officer/Principal

2004-09-08

Lubomir Nechev

Corporate Officer/Principal

2003-12-31

Thomas R. Ulich

Chief Tech/Sci/R&D Officer

2002-12-31

2003-12-31

Vincent J. Miles

Corporate Officer/Principal

2003-06-30

Victor E. Kotelianski

Corporate Officer/Principal

2003-03-31

David M. Konys

Corporate Officer/Principal

2003-03-31

Rachel Meyers

Chief Tech/Sci/R&D Officer

2003-03-31

Peter Barrett

Director/Board Member

2002-06-30

David Altreuter

Corporate Officer/Principal

Kathryn Morris

Public Communications Contact

Philip Chase

General Counsel

Donna T. Ward

Corporate Officer/Principal

Christoph Westphal

Director/Board Member	-	-
Founder	-	-

Stuart Pollard

Corporate Officer/Principal

Mary D. Trueblood

Comptroller/Controller/Auditor

Roy Lobb

Corporate Officer/Principal

Jürgen Soutschek

Chief Tech/Sci/R&D Officer

Ulrich Bodner

Corporate Officer/Principal

Edward E. Harlow

Corporate Officer/Principal

Jeffrey Behrens

Corporate Officer/Principal

Eric Ruby

General Counsel

Jian Xin Chen

Corporate Officer/Principal

David Neafus

Director of Finance/CFO

Zachary A. Zimmerman

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	20
Female	5

Of which Executive Committee

Male	8
Female	1

Of which Directors

Male	9
Female	2

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Companyâ€™s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Employees

2,500

Sector

Pharmaceuticals

More about the company